Moderna reported positive news from a study of its COVID-19 vaccine in 12 to 17-year-olds.
According to the company, zero participants in its study of 3,700 children contracted symptomatic COVID-19 during the trial.
Moderna said it now plans to ask the FDA to approve the vaccine for children 12 and up in the beginning of June. The agency could give the company the go-ahead within weeks.
So far, only one other vaccine has been approved for children in the U.S. — the Pfizer/BioNTech shot, which showed a similar rate of efficacy of around 100% in its study.
In the U.S., the CDC says that more than 5 million adolescents have gotten their first shot so far.
